Other longitudinal studies that followed patients with MS for one decade from the baseline assessment of serum NfL level, such as those performed by Thebault et al., and Chitnis et al., demonstrated the predictive role of NfL for the progression of disability, the risk of evolving towards a progressive form of MS, cerebral atrophy and increasing volume of T2 lesions [39,40]. This evidence concerns the gene NEFL and myeloid sarcoma.